Octreotide

Octreotide (brand names Sandostatin, Sandostatin LAR) is a synthetic 8-amino-acid cyclic peptide analog of native somatostatin-14. The molecule binds somatostatin receptor subtypes SSTR2 and SSTR5 with high affinity, mimicking the inhibitory effects of endogenous somatostatin on growth hormone secretion, insulin release, glucagon secretion, and gastrointestinal hormone release. It is administered as either subcutaneous injection (immediate-release Sandostatin, 2 to 4 times daily) or as long-acting intramuscular depot injection (Sandostatin LAR, once monthly). It was first FDA-approved on October 21, 1988 and is now marketed by Novartis.

The molecule's biological origin is somatostatin, a 14-amino-acid neuropeptide and hormone discovered in 1973. Native somatostatin has broad inhibitory effects across the endocrine system but is rapidly degraded with a half-life of approximately 3 minutes. The structural simplification to the 8-amino-acid octreotide preserves the receptor binding while extending the half-life to approximately 90 minutes for subcutaneous administration. The long-acting depot formulation extends the duration to approximately 4 weeks per dose through controlled release from biodegradable polymer microspheres.

FDA approval came on October 21, 1988 for:

• Acromegaly (excess growth hormone production, usually from pituitary adenoma)
• Severe diarrhea and flushing associated with metastatic carcinoid tumors
• Profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumors (VIPomas)

The indication has expanded over the decades through additional FDA approvals and clinical use to include neuroendocrine tumors, GI bleeding from esophageal varices, and other secretory disorders.

Clinical Indications and Evidence

Acromegaly. The first major approved indication. Octreotide reduces GH and IGF-1 levels in approximately 60 percent of patients to normal range, with symptomatic improvement in most patients. Surgical resection of pituitary adenoma remains first-line, but octreotide is used for surgically unresectable tumors, post-surgical persistent disease, and bridge-to-radiotherapy situations.

Neuroendocrine tumors (NETs). Octreotide is foundational therapy for functional NETs (carcinoid syndrome, VIPoma) and is also used for tumor growth control in non-functional NETs. The CLARINET trial (2014) and PROMID trial (2009) established the anti-tumor effects of somatostatin analogs in NETs.

Carcinoid syndrome. Octreotide controls flushing, diarrhea, and other symptoms of serotonin-secreting neuroendocrine tumors in approximately 80 percent of patients. The compound transformed carcinoid syndrome management from largely symptomatic to substantially controllable.

VIPoma. Direct suppression of VIP release controls the watery diarrhea that characterizes this rare condition. The indication was part of the original 1988 approval.

GI bleeding from esophageal varices. Octreotide reduces portal pressure through splanchnic vasoconstriction and is used as adjunctive therapy with endoscopic intervention in acute variceal bleeding. Not formally FDA-approved for this indication but widely used.

Other secretory disorders. Multiple off-label uses including chemotherapy-induced diarrhea, refractory dumping syndrome, refractory chylothorax, and various other secretory conditions.

The cumulative clinical experience spans 37 years across multiple indications, making octreotide one of the best-characterized peptide therapeutics in clinical use.

Octreotide binds somatostatin receptors (SSTRs), particularly SSTR2 and SSTR5 with high affinity. There are five SSTR subtypes (SSTR1 through SSTR5), and octreotide's selectivity profile differs from the broader binding of native somatostatin.

Growth hormone suppression. SSTR2 and SSTR5 activation on pituitary somatotrophs inhibits GH release. This is the central mechanism in acromegaly treatment. Octreotide suppresses GH levels and reduces IGF-1 (the downstream marker of GH excess) toward normal ranges in most acromegaly patients.

Insulin suppression. SSTR2 and SSTR5 activation on pancreatic beta cells inhibits insulin release. This can cause hyperglycemia or worsen diabetes control, particularly with long-term use.

Glucagon suppression. Similar inhibitory effect on pancreatic alpha cells, reducing glucagon release.

GI hormone suppression. Octreotide suppresses release of gastrin, cholecystokinin, secretin, motilin, vasoactive intestinal peptide, and other gastrointestinal peptide hormones. This is the mechanism behind its effects in carcinoid syndrome (suppressing serotonin and other vasoactive substance release) and VIPoma (directly suppressing VIP secretion).

GI motility effects. Reduced GI motility and slower gastric emptying. The effect contributes to the constipation that can occur with chronic use but is also the basis for the diarrhea-suppressing effects in carcinoid and VIPoma.

Splanchnic vasoconstriction. Reduced portal venous blood flow, which is the basis for octreotide use in acute variceal bleeding.

Anti-proliferative effects on neuroendocrine tumors. SSTR activation has direct anti-proliferative effects on certain neuroendocrine tumor cells, providing tumor growth control beyond symptomatic relief in carcinoid syndrome.

The dual immediate-release and long-acting formulations allow flexible dosing strategies. Immediate-release is used for acute conditions and initial dose-finding. Long-acting depot is used for chronic management once the optimal dose is established.

Regulatory status

United States. Multiple FDA approvals dating from October 21, 1988 (original Sandostatin immediate-release) through the Sandostatin LAR depot approval in 1998 and later label expansions.

EU and global. Approved in essentially all major regulatory jurisdictions. Octreotide is one of the most globally available specialty peptide therapeutics.

Generic availability. Generic octreotide acetate immediate-release became available after patent expiration. Generic LAR depot products have been more limited due to the complex manufacturing of the polymer microsphere formulation.

Pricing. Octreotide LAR is among the more expensive specialty medications. Monthly cost can exceed $8,000 to $15,000 depending on dose and formulation. Insurance coverage for approved indications is generally provided through specialty pharmacy channels.

WADA status. Octreotide is not currently on the WADA Prohibited List. The compound is not positioned as performance-enhancing. Some discussion of GH suppression effects in athletes has occurred but octreotide use in sport is not specifically regulated.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The 37-year clinical experience defines the octreotide safety profile.

Gallbladder disease. The most clinically significant long-term safety concern. Octreotide reduces gallbladder motility and increases the risk of gallstone formation. Approximately 30 to 50 percent of patients on chronic therapy develop gallstones, though many are asymptomatic. Pre-treatment and periodic gallbladder ultrasound monitoring is standard.

Glucose intolerance. SSTR2/5 activation on pancreatic beta cells suppresses insulin and produces glucose intolerance. Patients without baseline diabetes may develop impaired glucose tolerance. Patients with diabetes typically require adjustment of glucose-lowering therapy.

Gastrointestinal effects. Diarrhea, abdominal cramping, and steatorrhea (fatty stools) from suppressed pancreatic enzyme release. Generally improves with continued use.

Bradycardia and cardiac conduction abnormalities. Modest heart rate reduction. Generally clinically tolerable but warrants monitoring in patients with pre-existing cardiac disease.

Injection-site pain. Common with the long-acting intramuscular depot. The microsphere formulation produces a depot that can cause site discomfort.

Hypothyroidism. TSH suppression and primary hypothyroidism can develop with long-term use. Thyroid function monitoring is standard.

B12 deficiency. Long-term use can produce malabsorption and B12 deficiency.

The safety profile is well characterized and the risk-benefit assessment is favorable for the approved indications. The long-term safety profile is one of the better-characterized in specialty endocrinology pharmacotherapy.

The somatostatin analog class has three primary approved members:

Octreotide (Sandostatin). The first approved (1988). Available as immediate-release and long-acting depot. Binds SSTR2 and SSTR5. The reference somatostatin analog with the most extensive clinical experience.

Lanreotide (Somatuline). Approved in 2007 in the US (earlier in EU). Similar receptor binding profile to octreotide. Available as long-acting deep subcutaneous injection (not intramuscular). Pre-filled syringes allow some patients to self-administer.

Pasireotide (Signifor). Approved in 2012 for Cushing's disease. Binds SSTR1, SSTR2, SSTR3, and SSTR5 (broader receptor profile than octreotide and lanreotide). Higher rate of hyperglycemia due to the broader SSTR profile but better efficacy in Cushing's disease where SSTR5 is particularly relevant.

For acromegaly, octreotide and lanreotide are essentially interchangeable with similar efficacy and safety. The choice often comes down to patient preference (intramuscular octreotide vs subcutaneous lanreotide), insurance coverage, or specific clinical situations. Pasireotide is reserved for cases where the broader receptor profile provides clinical advantage.